CATMAT Statement: International traveller assessment

Volume 37 ACS-3, July 2011

Committee to Advise on Tropical Medicine and Travel (CATMAT)

Fever in the Returning International Traveller
Initial Assessment Guidelines


*Members: Dr. P.J. Plourde (Chair); Dr. C. Beallor; Dr. A. Boggild; Dr. J. Brophy; Dr. M. Crockett; Dr. W. Ghesquiere; Ms. A. Henteleff; Dr. A. McCarthy; Dr. K. L. McClean

Ex-Officio Representatives: Dr. G. Brunette, Dr. J. Creaghan, Dr. P. Charlebois; Dr. M. Tepper; Dr. P. McDonald; Dr. J. Given

Liaison Representatives: Dr. C. Greenaway; Dr. A. Pozgay; Dr. C. Hui; Dr. P. Teitelbaum

Member Emeritus: Dr. C. William L. Jeanes

Consultant: Dr. S. Schofield

 This Statement was prepared by Dr. A. Boggild, Dr. W. Ghesquiere, Dr. A. McCarthy and approved by CATMAT


Table of Contents


The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to tropical infectious diseases and health risks associated with international travel. PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and medical practices, and is disseminating this document for information purposes to both travellers and the medical community caring for travellers.

Persons administering or using drugs, vaccines, or other products should also be aware of the contents of the product monograph(s) or other similarly approved standards or instructions for use. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) or other similarly approved standards or instructions for use by the licensed manufacturer(s). Manufacturers have sought approval and provided evidence as to the safety and efficacy of their products only when used in accordance with the product monographs or other similarly approved standards or instructions for use.


Fever in the international traveller is a common syndrome seen in the post-travel setting, and may herald serious and life-threatening illness, the most important of which is malaria. All febrile patients or patients complaining of fever should therefore be asked about recent travel. While fever in the returning traveller may be due to benign self-limited infections, such as common agents of travellers’ diarrhea, or typical cosmopolitan causes unrelated to travel, it must be initially construed as a medical emergency, and warrants prompt and thorough evaluation. Accurate diagnosis and appropriate management necessitate a comprehensive travel history, including details about travel itinerary (destination, arrival and departure dates), the style of travel, pre-travel preparations, as well as potential exposures or medical treatment or care received abroad and a complete physical examination, with particular attention paid to systems with localizing symptoms or signs. The judicious use of laboratory testing should follow, with minimal essential tests outlined in the stepwise algorithm below.

This document is designed to:

  1. Guide front-line clinicians, including those working in the emergency room, walk-in clinics, and primary care practices, in the initial evaluation and management of fever in the returning traveller;
  2. Provide front-line clinicians without ready access to inpatient, internal medicine, or infectious diseases support with guidance in the evaluation and management of fever in the returning traveller beyond the initial phase.

Epidemiology of fever in the returning traveller

Fever in the returning traveller may be due to tropical infections or illnesses that have more of a cosmopolitan distribution globally. Numerous large series of illness after international travel have repeatedly identified malaria (20-30%) 1, acute travellers’ diarrhea (10-20%), and respiratory tract infections (10-15%) as the top causes of fever in travellers 211 (Table 1). Other common causes of fever in the returning traveller include dengue (5%), enteric fever due to Salmonella enterica serovar Typhi or Paratyphi (2-7%), skin and soft tissue infections (2-11%), rickettsioses (3%), urinary tract and sexually transmitted infections (2-3%), viral hepatitis (3%), and non-specific viral or mononucleosis-like syndrome (4-25%) 211. In febrile returning pediatric travellers, malaria (35%), viral syndromes (28%), unspecified febrile illnesses (11%), dengue (6%), and enteric fever (6%) are the most well-represented etiologies 12. Fever after international travel may be due to non-infectious causes as well, and include diverse etiologies such as drug reactions, pulmonary emboli, inflammatory conditions such as inflammatory bowel disease (IBD), malignancy, and hyperthyroidism.

Destination-specific analysis is helpful for establishing the epidemiology of travel-acquired illness 13 (Table 2). A history of travel to the Indian sub-continent in a febrile returned traveller should raise the suspicion of enteric fever: of 416 cases of imported typhoid in the United Kingdom over a three year period, 70% were imported from India and Pakistan 14. Malaria, on the other hand, illustrates a very different epidemiology among imported cases, with relative risks highest among travellers in sub-Saharan Africa 15. Unlike malaria, dengue fever is more likely to be acquired from South Asia, Southeast Asia and Latin America, rather than from Africa 13.

Purpose of travel is another useful piece of the travel history. People who travel for the purpose of visiting friends and relatives (VFR), including VFR children, constitute a particular risk group for acquisition of travel-related infections 12, particularly malaria 16 and enteric fever 4, and in the case of VFR children, acute viral hepatitis 17.

A thorough travel history with an understanding of what illnesses are possible based on dates and style of travel, geographic risks, and specific travel itinerary including activities and behaviors is essential to narrowing the differential diagnosis and ruling out life-threatening travel-acquired infections. Incubation period, defined as the time from initial exposure and infection to manifestation of symptoms, is also useful in refining the differential diagnosis. For instance, travel-acquired illnesses with short incubation periods including dengue, chikungunya, and travellers’ diarrhea, can be reliably excluded if symptoms do not manifest until >2 weeks after leaving the endemic area. Similarly, travel-acquired illnesses with long incubation periods such as tuberculosis (TB), hepatitis B (HBV), or visceral leishmaniasis can be discounted as travel-related if symptoms occur within days of returning from a one-week trip abroad. It is important to consider the earliest and latest possible dates of exposure in ill returned short- and long-term travellers to better inform the use of the incubation period in formulating a differential diagnosis. The following step-wise algorithm is designed to guide the clinician through his or her initial assessment of a returned traveller with fever, and in rare cases, to provide further guidance when inpatient support or specialist consultation is delayed or unavailable.

Table 1: Top specific diagnoses in single2;3;5–11 and multi-centre 4;12 analyses of fever in the returning traveller
1. Malaria (20-30%)
6. Skin and soft tissue infections (2-11%)
2.Acute travellers’ diarrhea / gastroenteritis (10-20%)
7. Rickettsioses, including African tick bite fever, Mediterranean spotted fever (tick typhus) (3%)
3. Respiratory tract infections (RTI) (10-15%)

8. Acute urinary tract infection / sexually transmitted infection (UTI / STI) (2-3%)
4. Dengue fever (5%)
9. Viral hepatitis (3%)
5. Enteric fever ( S. enterica serovar Typhi or Paratyphi ) (2-7%)
10. Mononucleosis- or viral-like syndrome (4-25%)
Table 2: Top specific diagnoses by region of travel in multi-centre 4;13 analyses of fever in the returning traveller
Sub-Saharan Africa

Malaria, RTI, diarrheal illness, skin and soft tissue infections
Southeast Asia
Dengue fever, RTI, diarrheal illness, malaria
South Central Asia / Indian sub-continent
Enteric fever, dengue fever, malaria, diarrheal illness
South America
Diarrheal illness, RTI, dengue fever, malaria
Caribbean / Central Americ
Diarrheal illness, RTI, dengue fever, malaria

Evaluation of fever in the returning traveller

Objective: Exclusion of life-threatening, highly communicable, or treatable illness

STEP 1: History of travel
A. Pre-travel preparations Pre-travel consultation: date, location, contact details
Immunizations received and dates; oral versus injectable formulation if applicable; completion of full vaccination series for travel and for routine childhood immunizations
Malaria prophylaxis: drug, dose, schedule, adherence, duration, side effects
Other prophylaxis: drug, dose, schedule, adherence, duration, side effects
Other personal protective measures: standby treatment of malaria / travellers’ diarrhea; bednets; clothing; insecticide use
Air transportation preparations: deep vein thrombosis (DVT) prophylaxis, medications for jet lag
Environmental risk preparations: sun, extreme heat, altitude
B. Specific travel itinerary Dates of travel (approximation of incubation period)
Season of travel: rainy, dry
Specific destinations: regions; urban, rural; proximity to fresh water; jungle, desert
Reason for travel: tourism, business, visiting friends and relatives (VFR), other
Style of travel: accommodation; off typical tourist routes; camping, trekking
Local population: possible TB contacts, outbreaks, illnesses
Transportation: crowding; use of animals such as camels, elephants
C. Exposure history* Street foods / Local water (enteric fever, travellers’ diarrhea)
Arthropod bites (malaria, dengue, chikungunya, arboviruses, Rickettsia, African trypanosomiasis)
Uncooked meat / unpasteurized dairy (trichinosis, brucellosis, toxoplasmosis)
Blood and body fluid exposure: sexual encounters, tattoos, piercings, injections including immunizations, intravenous (IV) drug use, and rabies post-exposure prophylaxis (PEP) (human immunodeficiency virus [HIV], HBV, hepatitis C virus [HCV], herpes simplex virus [HSV], syphilis, gonorrhea (gonococcus) / Chlamydia trachomatis [GC/CT])

Fresh water activities: swimming, kayaking, rafting (schistosomiasis, leptospirosis)

Animal exposures (Q-fever, brucellosis, tularemia, anthrax, rabies, Crimean-Congo hemorrhagic fever)

Safari (rickettsioses, African trypanosomiasis)

*For epidemiology of specific diseases, please refer to websites of the WHO (World Health Organization) (, or the Public Health Agency of Canada (PHAC) (, the U.S. Centers for Disease Control and Prevention (CDC) (

STEP 2: History of fever and clinical features
A. Fever pattern Daily / Continuous Common: malaria, travellers’ diarrhea, RTI, enteric fever
Uncommon: rickettsioses
Rare: HIV, Q-fever, brucellosis, TB
Saddleback (biphasic) Common: malaria, dengue
Uncommon: leptospirosis
Rare: yellow fever, arbovirus
Relapsing Common: malaria, enteric fever
Uncommon: amoebic liver abscess, leptospirosis
Rare: HIV, Q-fever, brucellosis, TB, endemic mycoses, borreliosis
B. Incubation period (Definition: time from exposure / infection to disease manifestation) <2 weeks Common: malaria, travellers’ diarrhea, dengue, RTI, influenza
Uncommon: rickettsioses, meningitis
Rare: yellow fever, arbovirus, viral hemorrhagic fever
2-6 weeks Common: malaria, enteric fever
Uncommon: hepatitis A virus (HAV), katayama fever, amoebic liver abscess, hepatitis E virus
Rare: HIV, Q-fever, brucellosis, East African trypanosomiasis
>6 weeks Common: malaria
Uncommon: HBV, amoebic liver abscess, TB
Rare: HIV, visceral leishmaniasis, endemic mycoses, West African trypanosomiasis, HCV
C. Fever duration at visit <7 days Common: malaria, travellers’ diarrhea, dengue, enteric fever, RTI
Uncommon: rickettsioses, leptospirosis, meningitis
Rare: yellow fever, arbovirus
7-21 days Common: malaria, enteric fever
Uncommon: rickettsioses, viral hepatitis, leptospirosis
Rare: HIV, Q-fever, brucellosis
>21 days Common: malaria, enteric fever
Uncommon: TB, HBV, bacterial endocarditis
Rare: HIV, Q-fever, brucellosis

Arbovirus: includes other mosquito-borne viruses such as chikungunya, mayaro, O’nyong-nyong, Ross River, sindbis, equine encephalitis, WNV, La Crosse, Oropouche, Rift Valley fever, and tick-borne viruses such as Kyasanur Forest, Omsk, and Crimean-Congo hemorrhagic fever

STEP 3: Primary laboratory investigations after comprehensive physical examination including thorough skin examination
Returned travellers with fever should undergo at least the following investigations

Consider the following supplementary tests based on history and epidemiology:
E. coli
Cyclospora, Cryptosporidium, Entamoeba histolytica, Giardia

**Consider referral to a person with expertise in tropical medicine or infectious diseases (as available) if primary laboratory investigations yield no definitive diagnosis and patient is not improving, or patient is at risk of complications (e.g., pregnant women, children, underlying co-morbidities, immunocompromised, etc). Additional support, if required, may be sought through the Canadian Malaria Network (**

STEP 4: Empiric management for presumed travellers’ diarrhea or enteric fever ± rickettsioses in adult travellers i, ii

Consider if patient fulfills the following criteria:

  1. Undifferentiated fever; and
  2. Negative malaria smears 1; and
  3. Patient has not improved over past 48-72 hours; and
  4. All other cultures and tests have been ordered and are pending or non-contributory
Travelled to the Indian Sub-Continent or Southeast Asia Travelled outside the Indian Sub-Continent or Southeast Asia
  1. Azithromycin 1000 mg po once daily x 5 days (alternative: 1000 mg po once on day 1, then 500 mg once daily x 6 days) ±
  2. Doxycycline** 100 mg po BID x 7 days
  1. Ciprofloxacin 500 mg po BID x 3-7* days ±
  2. Doxycycline** 100 mg po BID x 7 days
  1. Step 4 is not a substitute for Step 3 (Primary laboratory investigations after comprehensive physical examination), nor should empiric therapy preclude ongoing and close follow-up of the patient. Undifferentiated fever refers to fever without prominent localizing symptoms or signs, and is often the presenting complaint in many travel-acquired illnesses including malaria and enteric fever. It is essential that all febrile returned travellers to potentially malarious areas undergo malaria screening with 2-3 smears over 48 hours ± rapid antigen testing. Adult patients who have not improved substantially, either subjectively or objectively, over the previous 48-72 hours are candidates for empiric therapy as above while investigations are pending. These patients require frequent clinical reassessment (every 1-2 days) until either a diagnosis is made and definitive therapy instituted, or until subjective and objective clinical improvement is achieved. Prior to initiation of empiric therapy as above, all samples for microbiological testing should have been obtained as outlined in Step 3.
  2. Caution must be exercised in the evaluation and empiric therapy of fever in children, given the higher rate of complicated disease in this age group. Clinicians should have a low threshold for admission and initiation of IV therapy for presumed enteric fever, in which case a parenteral third generation cephalosporin (ceftriaxone or cefotaxime) could be considered. Similarly, use of doxycycline and ciprofloxacin is not routine in children and generally reserved for specific cases in which the benefits of these antibiotics are felt to exceed the potential risks (permanent dental staining, arthropathy). Consultation with a specialist experienced in the treatment of pediatric tropical diseases should be considered.

*3-day regimen for suspected travellers’ diarrhea; 7-10-day regimen for suspected enteric fever

**this will also cover leptospirosis

Appendix I. Specific tests to rule out common travel-acquired infections that can cause fever

Travel-acquired infection Diagnostic test(s)
  1. Thick and thin blood smears ± antigen-based dipstick assay; minimum 2-3 times over 24-48 hours
  2. Blood for malaria polymerase chain reaction (PCR) if smears and/or dipstick negative but index of suspicion high
Acute travellers’ diarrhea / gastroenteritis (60-80% bacterial)
  1. Stool culture for enteropathogens x 1 (will detect Salmonella, Shigella, Campylobacter, E. coli O157:H7, and often Yersinia)
  2. Stool for Clostridium difficile toxin
  3. Stool for ova and parasites (O&P) x 3 (be aware that not all laboratories screen for all protozoa, including coccidia, routinely; check with local laboratory for special staining request requirements)
  4. Amoebic serology ± stool Entamoeba histolytica ELISA if bloody stool
  1. Chest x-ray
  2. Nasopharyngeal swab (NP) swab for viral antigen testing or PCR (influenza A/B, respiratory syncytial virus [RSV], adenovirus, parainfluenza virus 1-3, human metapneumovirus, coronavirus)
  3. Sputum for culture and susceptibility (C&S) and acid-fast bacilli (AFB) (as directed by index of suspicion)
  4. Legionella urine antigen
  5. Epstein-Barr virus (EBV) – EBV monospot unreliable in children ≤ 4 years of age; EBV viral capsule antigen (VCA) IgM/IgG, EBV nuclear antigen (EBNA) IgM/IgG
  6. (Serology for Q-fever, Histoplasma, Blastomyces, Coccidioides as directed by index of suspicion and travel exposures; urinary antigen for Histoplasma)
  1. Acute and convalescent sera (2 weeks after) for dengue IgM and IgG
Enteric fever due to Salmonella enterica serovar Typhi or Paratyphi
  1. Blood culture x 2 (caution if the patient has received antibiotics as they may have negative blood cultures)
  2. Stool culture
  3. (Bone marrow aspirate and culture)
Skin and soft tissue infection
  1. Clinical diagnosis
  2. Skin swab for methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) if exudative
  3. If ulcerative, smears for Giemsa-stain, biopsy or aspirate for Leishmania culture or PCR; consider skin swab to rule out ecthyma ulcer due to Staphylococcus or Pseudomonas
  1. Clinical diagnosis – presence of an eschar is diagnostic (but may not be present)
  2. Acute and convalescent sera for rickettsial serology
Acute UTI / STI
  1. Urinalysis and urine microscopy
  2. Urine culture
  3. Urine and/or endocervical swabs for GC/CT
  4. Swab for viral PCR of genital vesicles
  5. Blood for HIV, HBV, HCV and syphilis serology
Viral hepatitis
  1. HAV – HAV IgM, HAV IgG (unless history of previous vaccination)
  2. HBV – HBsAg (surface antigen), HBsAb (surface antibody), HBcAb (core antibody), HBeAg (e antigen), HBeAb (e antibody); HBV DNA
  3. HCV – HCV total antibody
  4. Hepatitis D virus (HDV) – Anti-HDV antigen; serum HDV RNA reverse transcription PCR (RT-PCR)
  5. Hepatitis E virus (HEV) – Anti-HEV IgM antibody; blood or stool for HEV PCR
  6. EBV – EBV monospot unreliable in children ≤ 4 years of age; EBV VCA IgM/IgG, EBNA IgM/IgG
  7. Cytomegalovirus (CMV) – IgM/IgG; CMV antigenemia; serum for CMV PCR
Other potentially travel-acquired infections diagnosed by serology
  1. Viral – Chikungunya, arboviruses
  2. Bacterial – Q-fever, Brucella (can also be cultured from blood or bone marrow), Leptospira
  3. Fungal – Histoplasma, Blastomyces, Coccidioides, Cryptococcus (can detect by serum or CSF or urinary antigen also)
  4. Parasitic – Strongyloides, Schistosoma, Amoebiasis (can also detect in stool O&P and by stool ELISA)

Appendix II. Additional resources for guidance on fever in the returning traveller

Committee to Advise on Tropical Medicine and Travel (CATMAT) Statements

Canadian Recommendations for the Prevention and Treatment of Malaria among International Travellers (2009) -

Statement On Persistent Diarrhea In The Returned Traveller (2006) -

Statement on Travellers and Sexually Transmitted Infections (2006) -

Public Health Agency of Canada

Travel Health Notices website -

National Microbiology Laboratory -

United States - Centers for Disease Control and Prevention -

Viral Special Pathogens Branch, NCID -

VSPB specimen submission info - (phone number 404-639-2888)


World Health Organization outbreak site –

Promed –

Articles for further reading

Johnston V, Stockley JM, Dockrell D, et al. Fever in returned travellers presenting in the United Kingdom: Recommendations for investigation and initial management. J Infection 2009;59:1-18.

Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relationship to place of exposure in ill returned travellers. N Engl J Med 2006;354:119-130.

Boggild AK, Page AV, Keystone JS, Morris AM, Liles WC. Delay in diagnosis: malaria in a returning traveller. CMAJ 2009;180(11):1129-1131. Available at:

Rynor B. Dengue fever on the rise at tourist getaways. CMAJ 2010;182(4):E195-196. Available at:

Szakacs TA, McCarthy AE. An all-inclusive vacation. CMAJ 2007;177(1):29-31. Available at:

Daneman N, Slinger R. Tache noire. CMAJ 2008;178(7):841. Available at:

Acid fast bacilli
Bis in die (twice per day)
Committee to Advise on Tropical Medicine and Travel
Centers for Disease Control and Prevention
Cerebrospinal fluid
Culture and susceptibility
Deoxyribonucleic acid
Deep vein thrombosis
Epstein-Barr virus
Epstein-Barr virus nuclear antigen
Epstein-Barr virus viral capsule antigen
Enzyme-linked immunosorbent assay
Gonorrhea (gonococcus) / Chlamydia trachomatis
Hepatitis A virus
Hepatitis B core antibody
Hepatitis B e antigen
Hepatitis B surface antibody
Hepatitis B surface antigen
Hepatitis B virus
Hepatitis C virus
Hepatitis D virus
Hepatitis E virus
Human immunodeficiency virus
Herpes simplex virus
Inflammatory bowel disease
Immunoglobulin M
Immunoglobulin G
Methicillin-resistant Staphylococcus aureus
Methicillin-sensitive Staphylococcus aureus
Nasopharyngeal swab
Ova and parasites
Polymerase chain reaction
Post-exposure prophylaxis
Public Health Agency of Canada
Per os (by mouth)
Ribonucleic acid
Respiratory syncytial virus
Reverse transcription polymerase chain reaction
Respiratory tract infection
Sexually transmitted infection
Urinary tract infection
Visiting friends and relatives
World Health Organization
West Nile virus


  1. Committee to Advice on Tropical Medicine and Travel. Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers. CCDR 2009;34:1-45.
  2. Steffen R, Rickenbach M, Wilhem U, Helminger A, Schar M. Health problems after travel to developing countries. J Infect Dis 1987;156:84-91.
  3. Hill D. Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 2000;7:259-266.
  4. Wilson M, Weld L, Boggild A et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007;44:1560-1568.
  5. Bottieau E, Clerinx J, Schrooten W et al. Etiology and outcome of fever after a stay in the tropics. Arch Intern Med 2006;166:1642-1648.
  6. Doherty J, Grant A, Bryceson A. Fever as the presenting complaint of travellers returning from the tropics. QJM 1995;88:277-281.
  7. O'Brien D, Tobin S, Brown G, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001;33:603-609.
  8. Antinori S, Galimberti L, Gianelli E et al. Prospective observational study of fever in hospitalized returning travelers and migrants from tropical areas, 1997-2001. J Travel Med 2004;11:135-142.
  9. Parola P, Soula G, Gazin P, Foucault C, Delmont J, Brouqui P. Fever in travelers returning from tropical areas: prospective observational study of 613 cases hospitalised in Marseilles, France, 1999-2003. Travel Med Infect Dis 2006;4:61-70.
  10. West N, Riordan F. Fever in returned travellers: a prospective review of hospital admissions for a 2(1/2) year period. Arch Dis Child 2003;88:432-434.
  11. Klein J, Millman G. Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics. BMJ 1998;316:1425-1426.
  12. Hagmann S, Neugebauer R, Schwartz E et al. Illness in children after international travel: analysis from the GeoSentinel Surveillance Network. Pediatrics 2010;125:e1072-e1080.
  13. Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of Disease and Relation to Place of Exposure among Ill Returned Travelers. N Engl J Med 2006;354:119-130.
  14. Cooke F, Day M, Wain J, Ward L, Threlfall E. Cases of typhoid fever imported into England, Scotland and Wales (2000-2003). Trans R Soc Trop Med Hyg 2007;101:398-404.
  15. Freedeman DO. Malaria prevention in short-term travellers. N Engl J Med 2008;359:603-612.
  16. Centers for Disease Control and Prevention. CDC surveillance summaries - malaria surveillance: United States 2004. MMWR 2006;55:23-37.
  17. Behrens R, Collins M, Botto B, Heptonstall J. Risk for British travellers of acquiring hepatitis A. BMJ 1995;311:193.

Search CCDR

Page details

Date modified: